Philipp N. Harter

Essen, NW 45136, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 328 publications

The science and conduct of surgical trials in gynecologic oncology: A practical framework.

The science and conduct of surgical trials in gynecologic oncology: A practical framework.

Journal: Gynecologic oncology

Published: August 05, 2026

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners" [International Journal of Gynecological Cancer 36 (2026) 104753].

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners" [International Journal of Gynecological Cancer 36 (2026) 104753].

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 02, 2026

Gynecologic Cancer InterGroup code of conduct for diversity in gynecological cancer trials: a clinical guide from the Berlin Gynecologic Cancer InterGroup meeting.

Gynecologic Cancer InterGroup code of conduct for diversity in gynecological cancer trials: a clinical guide from the Berlin Gynecologic Cancer InterGroup meeting.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 15, 2026

Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

Journal: JCO precision oncology

Published: June 12, 2026

Secondary cytoreduction for ovarian cancer relapse: results from the high surgical quality, multi-center "Surgery in Recurrent Ovarian Cancer Research Consortium (SURROC-CON)".

Secondary cytoreduction for ovarian cancer relapse: results from the high surgical quality, multi-center "Surgery in Recurrent Ovarian Cancer Research Consortium (SURROC-CON)".

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 07, 2026

Treatment and outcome of elderly patients with presumed early ovarian cancer in Germany: real-world observations from the quality-assurance program of the AGO Study Group.

Treatment and outcome of elderly patients with presumed early ovarian cancer in Germany: real-world observations from the quality-assurance program of the AGO Study Group.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 13, 2026

Impact of Anatomical Site on RNA-Based Molecular Subtypes in Paired High-Grade Serous Ovarian Carcinoma Samples.

Impact of Anatomical Site on RNA-Based Molecular Subtypes in Paired High-Grade Serous Ovarian Carcinoma Samples.

Journal: Cancers

Published: May 09, 2026

Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners.

Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 28, 2026

Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners.

Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 28, 2026

Reconsidering the control arm in hyperthermic intra-peritoneal chemotherapy trials for epithelial ovarian cancer: are we comparing equivalent chemotherapy exposure?

Reconsidering the control arm in hyperthermic intra-peritoneal chemotherapy trials for epithelial ovarian cancer: are we comparing equivalent chemotherapy exposure?

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 12, 2026

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Journal: Gynecologic oncology

Published: February 01, 2026

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 03, 2025

Showing 1-12 of 328

Last Updated: 09/26/2026